TELA Bio (TELA) Stock Forecast, Price Target & Predictions
TELA Stock Forecast
TELA Bio stock forecast is as follows: an average price target of $14.00 (represents a 428.30% upside from TELA’s last price of $2.65) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
TELA Price Target
The average price target for TELA Bio (TELA) is $14.00 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $20.00 to $8.00. This represents a potential 428.30% upside from TELA's last price of $2.65.
TELA Analyst Ratings
According to 2 Wall Street analysts, TELA Bio's rating consensus is 'Buy'. The analyst rating breakdown for TELA stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
TELA Bio Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 13, 2024 | Matt O'Brien | Piper Sandler | $8.00 | $4.01 | 99.50% | 201.89% |
| May 22, 2024 | Kyle Rose | Canaccord Genuity | $14.00 | $6.20 | 125.81% | 428.30% |
| May 10, 2024 | Matt O'Brien | Piper Sandler | $10.00 | $5.78 | 73.01% | 277.36% |
| Nov 10, 2022 | - | JMP Securities | $20.00 | $8.10 | 146.91% | 654.72% |
| Nov 09, 2022 | Matt O'Brien | Piper Sandler | $15.00 | $6.50 | 130.77% | 466.04% |
The latest TELA Bio stock forecast, released on Aug 13, 2024 by Matt O'Brien from Piper Sandler, set a price target of $8.00, which represents a 99.50% increase from the stock price at the time of the forecast ($4.01), and a 201.89% increase from TELA last price ($2.65).
TELA Bio Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 3 |
| Avg Price Target | - | $8.00 | $10.67 |
| Last Closing Price | $2.65 | $2.65 | $2.65 |
| Upside/Downside | -100.00% | 201.89% | 302.64% |
In the current month, the average price target of TELA Bio stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to TELA Bio's last price of $2.65. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 13, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| May 22, 2024 | Canaccord Genuity | Buy | Buy | Hold |
| May 10, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Nov 09, 2022 | Piper Sandler | Overweight | Overweight | Hold |
TELA Bio's last stock rating was published by Piper Sandler on Aug 13, 2024. The company gave TELA a "Overweight" rating, the same as its previous rate.
TELA Bio Financial Forecast
TELA Bio Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $17.00M | $15.05M | $14.49M | $11.91M | $11.62M | $11.16M | $10.41M | $8.23M | $8.37M | $7.65M | $7.56M | $5.88M | $5.67M | $5.31M | $3.51M | $3.73M | $4.86M | $3.97M |
| Avg Forecast | $32.64M | $30.09M | $29.83M | $26.73M | $27.33M | $22.87M | $22.33M | $21.23M | $22.95M | $18.75M | $18.45M | $16.32M | $16.46M | $16.20M | $14.39M | $12.01M | $13.18M | $10.86M | $10.12M | $7.94M | $7.97M | $7.55M | $6.31M | $5.46M | $5.81M | $4.57M | $1.94M | $3.66M | $4.17M | $3.94M |
| High Forecast | $33.43M | $30.81M | $30.54M | $27.37M | $27.99M | $23.42M | $22.87M | $21.74M | $23.50M | $18.85M | $18.89M | $16.71M | $16.71M | $16.59M | $14.74M | $12.30M | $13.50M | $11.12M | $10.27M | $8.06M | $8.08M | $7.66M | $6.40M | $5.54M | $5.89M | $4.64M | $1.96M | $3.72M | $4.23M | $3.99M |
| Low Forecast | $31.69M | $29.20M | $28.95M | $25.94M | $26.53M | $22.20M | $21.68M | $20.61M | $22.28M | $18.66M | $17.91M | $15.84M | $16.21M | $15.73M | $13.97M | $11.66M | $12.80M | $10.54M | $9.95M | $7.81M | $7.83M | $7.42M | $6.20M | $5.37M | $5.71M | $4.49M | $1.90M | $3.60M | $4.10M | $3.87M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.03% | 0.93% | 1.01% | 0.99% | 0.88% | 1.03% | 1.03% | 1.04% | 1.05% | 1.01% | 1.20% | 1.08% | 0.98% | 1.16% | 1.81% | 1.02% | 1.17% | 1.01% |
TELA Bio's average Quarter revenue forecast for Mar 24 based on 1 analysts is $16.32M, with a low forecast of $15.84M, and a high forecast of $16.71M. TELA's average Quarter revenue forecast represents a -4.00% decrease compared to the company's last Quarter revenue of $17.00M (Dec 23).
TELA Bio EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $-12.12M | $-9.62M | $-9.49M | $-10.78M | $-8.80M | $-9.48M | $-10.58M | $-9.80M | $-14.75M | $-7.22M | $-7.26M | $-7.11M | $-6.75M | $-6.67M | $-5.08M | $-6.21M | $-5.50M | $-3.62M |
| Avg Forecast | $-30.57M | $-28.17M | $-27.93M | $-25.03M | $-25.60M | $-21.41M | $-20.91M | $-19.88M | $-21.49M | $-17.56M | $-17.28M | $-15.28M | $-15.41M | $-15.18M | $-13.48M | $-11.25M | $-12.35M | $-7.18M | $-9.48M | $-5.00 | $-7.46M | $-7.07M | $-5.91M | $-5.92M | $-5.44M | $-4.28M | $-1.81M | $-5.43M | $-3.91M | $-3.69M |
| High Forecast | $-29.67M | $-27.35M | $-27.11M | $-24.30M | $-24.85M | $-20.79M | $-20.30M | $-19.30M | $-20.86M | $-17.47M | $-16.77M | $-14.83M | $-15.18M | $-14.73M | $-13.08M | $-10.92M | $-11.98M | $-5.74M | $-9.32M | $-4.00 | $-7.33M | $-6.95M | $-5.81M | $-4.74M | $-5.35M | $-4.20M | $-1.78M | $-4.35M | $-3.84M | $-3.62M |
| Low Forecast | $-31.30M | $-28.85M | $-28.60M | $-25.63M | $-26.21M | $-21.93M | $-21.42M | $-20.36M | $-22.01M | $-17.65M | $-17.69M | $-15.65M | $-15.64M | $-15.54M | $-13.80M | $-11.52M | $-12.64M | $-8.61M | $-9.62M | $-6.00 | $-7.57M | $-7.18M | $-6.00M | $-7.11M | $-5.52M | $-4.34M | $-1.84M | $-6.52M | $-3.97M | $-3.74M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.79% | 0.63% | 0.70% | 0.96% | 0.71% | 1.32% | 1.12% | 1959400.00% | 1.98% | 1.02% | 1.23% | 1.20% | 1.24% | 1.56% | 2.80% | 1.14% | 1.41% | 0.98% |
undefined analysts predict TELA's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than TELA Bio's previous annual EBITDA (undefined) of $NaN.
TELA Bio Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $-12.89M | $-10.96M | $-10.79M | $-14.05M | $-9.77M | $-11.94M | $-13.35M | $-11.88M | $-2.35M | $-8.27M | $-8.26M | $-8.14M | $-7.79M | $-7.70M | $-6.08M | $-7.22M | $-6.53M | $-4.67M |
| Avg Forecast | $125.78K | $-1.41M | $-1.71M | $-3.72M | $-5.67M | $-6.99M | $-6.66M | $-8.14M | $-7.00M | $-10.01M | $-11.26M | $-12.05M | $-10.99M | $-11.86M | $-12.88M | $-13.49M | $-13.14M | $-8.22M | $-14.91M | $-5.00 | $-12.86M | $-12.78M | $-12.69M | $-6.78M | $-11.85M | $-11.90M | $-14.61M | $-6.32M | $-14.67M | $-13.81M |
| High Forecast | $129.71K | $-1.36M | $-1.65M | $-3.58M | $-5.46M | $-6.72M | $-6.41M | $-7.83M | $-6.74M | $-8.39M | $-10.83M | $-11.60M | $-10.49M | $-11.41M | $-12.39M | $-12.98M | $-12.64M | $-6.57M | $-14.58M | $-4.00 | $-12.58M | $-12.50M | $-12.40M | $-5.42M | $-11.58M | $-11.63M | $-14.29M | $-5.05M | $-14.35M | $-13.50M |
| Low Forecast | $120.98K | $-1.45M | $-1.77M | $-3.84M | $-5.85M | $-7.21M | $-6.87M | $-8.39M | $-7.22M | $-11.63M | $-11.61M | $-12.43M | $-11.24M | $-12.23M | $-13.28M | $-13.91M | $-13.55M | $-9.86M | $-15.19M | $-7.00 | $-13.11M | $-13.02M | $-12.93M | $-8.14M | $-12.07M | $-12.12M | $-14.89M | $-7.58M | $-14.95M | $-14.07M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.17% | 0.92% | 0.84% | 1.04% | 0.74% | 1.45% | 0.90% | 2376000.00% | 0.18% | 0.65% | 0.65% | 1.20% | 0.66% | 0.65% | 0.42% | 1.14% | 0.45% | 0.34% |
TELA Bio's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. TELA's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
TELA Bio SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $21.22M | $18.20M | $18.05M | $17.10M | $14.89M | $14.70M | $14.69M | $12.84M | $11.59M | $10.41M | $10.47M | $9.05M | $9.25M | $8.95M | $6.27M | $7.79M | $7.87M | $5.94M |
| Avg Forecast | $48.36M | $44.57M | $44.19M | $39.60M | $40.49M | $33.87M | $33.08M | $31.45M | $34.00M | $27.78M | $27.33M | $24.17M | $24.38M | $24.01M | $21.32M | $17.80M | $19.53M | $10.35M | $14.99M | $6.00 | $11.80M | $11.19M | $9.35M | $8.09M | $8.60M | $6.77M | $2.87M | $5.43M | $6.18M | $5.83M |
| High Forecast | $49.52M | $45.64M | $45.25M | $40.55M | $41.46M | $34.69M | $33.88M | $32.21M | $34.82M | $27.93M | $27.99M | $24.75M | $24.75M | $24.58M | $21.83M | $18.22M | $20.00M | $12.42M | $15.21M | $8.00 | $11.97M | $11.35M | $9.49M | $8.21M | $8.73M | $6.87M | $2.91M | $5.51M | $6.27M | $5.92M |
| Low Forecast | $46.94M | $43.26M | $42.89M | $38.43M | $39.30M | $32.88M | $32.11M | $30.53M | $33.00M | $27.64M | $26.53M | $23.47M | $24.02M | $23.30M | $20.70M | $17.27M | $18.96M | $8.28M | $14.74M | $5.00 | $11.60M | $11.00M | $9.19M | $7.95M | $8.46M | $6.65M | $2.82M | $5.33M | $6.08M | $5.73M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.87% | 0.76% | 0.85% | 0.96% | 0.76% | 1.42% | 0.98% | 2139333.33% | 0.98% | 0.93% | 1.12% | 1.12% | 1.07% | 1.32% | 2.19% | 1.44% | 1.27% | 1.02% |
TELA Bio's average Quarter SG&A projection for Mar 24 is $24.17M, based on 1 Wall Street analysts, with a range of $23.47M to $24.75M. The forecast indicates a 13.94% rise compared to TELA last annual SG&A of $21.22M (Dec 23).
TELA Bio EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $-0.53 | $-0.45 | $-0.46 | $-0.73 | $-0.51 | $-0.71 | $-0.92 | $-0.82 | $-0.16 | $-0.57 | $-0.57 | $-0.56 | $-0.54 | $-0.53 | $-0.53 | $-0.63 | $-1.22 | $-0.44 |
| Avg Forecast | $0.01 | $-0.06 | $-0.07 | $-0.15 | $-0.23 | $-0.28 | $-0.27 | $-0.33 | $-0.28 | $-0.41 | $-0.46 | $-0.49 | $-0.45 | $-0.48 | $-0.52 | $-0.55 | $-0.53 | $-0.60 | $-0.60 | $-0.54 | $-0.52 | $-0.52 | $-0.51 | $-0.48 | $-0.48 | $-0.48 | $-0.59 | $-0.57 | $-0.59 | $-0.56 |
| High Forecast | $0.01 | $-0.06 | $-0.07 | $-0.15 | $-0.22 | $-0.27 | $-0.26 | $-0.32 | $-0.27 | $-0.34 | $-0.44 | $-0.47 | $-0.43 | $-0.46 | $-0.50 | $-0.53 | $-0.51 | $-0.57 | $-0.59 | $-0.53 | $-0.51 | $-0.51 | $-0.50 | $-0.47 | $-0.47 | $-0.47 | $-0.58 | $-0.55 | $-0.58 | $-0.55 |
| Low Forecast | - | $-0.06 | $-0.07 | $-0.16 | $-0.24 | $-0.29 | $-0.28 | $-0.34 | $-0.29 | $-0.47 | $-0.47 | $-0.50 | $-0.46 | $-0.50 | $-0.54 | $-0.56 | $-0.55 | $-0.62 | $-0.62 | $-0.55 | $-0.53 | $-0.53 | $-0.52 | $-0.49 | $-0.49 | $-0.49 | $-0.60 | $-0.58 | $-0.61 | $-0.57 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.19% | 0.94% | 0.88% | 1.33% | 0.96% | 1.19% | 1.52% | 1.52% | 0.31% | 1.10% | 1.11% | 1.18% | 1.12% | 1.10% | 0.89% | 1.11% | 2.05% | 0.78% |
According to undefined Wall Street analysts, TELA Bio's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to TELA previous annual EPS of $NaN (undefined).
TELA Bio Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| TELA | TELA Bio | $2.65 | $14.00 | 428.30% | Buy |
| DCTH | Delcath Systems | $9.54 | $22.00 | 130.61% | Buy |
| CVRX | CVRx | $7.85 | $15.83 | 101.66% | Buy |
| OFIX | Orthofix Medical | $16.76 | $31.00 | 84.96% | - |
| NPCE | NeuroPace | $7.43 | $12.88 | 73.35% | Buy |
| FNA | Paragon 28 | $7.39 | $11.50 | 55.62% | Buy |
| SGHT | Sight Sciences | $6.95 | $10.33 | 48.63% | Hold |
| LUNG | Pulmonx | $8.31 | $12.25 | 47.41% | Buy |
| VREX | Varex Imaging | $11.82 | $17.00 | 43.82% | Buy |
| SIBN | SI-BONE | $15.73 | $20.00 | 27.15% | Buy |
| KIDS | OrthoPediatrics | $32.28 | $40.80 | 26.39% | Buy |
| RXST | RxSight | $54.96 | $68.60 | 24.82% | Buy |
| TCMD | Tactile Systems | $13.86 | $16.00 | 15.44% | Buy |
| TMDX | TransMedics Group | $151.42 | $156.86 | 3.59% | Buy |
| CLPT | ClearPoint Neuro | $12.59 | $12.00 | -4.69% | Buy |
TELA Forecast FAQ
Is TELA Bio a good buy?
Yes, according to 2 Wall Street analysts, TELA Bio (TELA) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 100.00% of TELA's total ratings.
What is TELA's price target?
TELA Bio (TELA) average price target is $14 with a range of $8 to $20, implying a 428.30% from its last price of $2.65. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will TELA Bio stock go up soon?
According to Wall Street analysts' prediction for TELA stock, the company can go up by 428.30% (from the last price of $2.65 to the average price target of $14), up by 654.72% based on the highest stock price target, and up by 201.89% based on the lowest stock price target.
Can TELA Bio stock reach $4?
TELA's average twelve months analyst stock price target of $14 supports the claim that TELA Bio can reach $4 in the near future.
What are TELA Bio's analysts' financial forecasts?
TELA Bio's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $93.77M (high $96.02M, low $91.02M), average EBITDA is $-87.807M (high $-85.232M, low $-89.915M), average net income is $-27.458M (high $-26.411M, low $-28.315M), average SG&A $138.91M (high $142.24M, low $134.83M), and average EPS is $-1.113 (high $-1.071, low $-1.148). TELA's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $119.29M (high $122.15M, low $115.79M), average EBITDA is $-112M (high $-108M, low $-114M), average net income is $-6.721M (high $-6.456M, low $-6.939M), average SG&A $176.71M (high $180.95M, low $171.53M), and average EPS is $-0.273 (high $-0.262, low $-0.281).
Did the TELA's actual financial results beat the analysts' financial forecasts?
Based on TELA Bio's last annual report (Dec 2023), the company's revenue was $58.45M, which missed the average analysts forecast of $59.07M by -1.04%. Apple's EBITDA was $-44.075M, missing the average prediction of $-55.316M by -20.32%. The company's net income was $-46.664M, missing the average estimation of $-49.221M by -5.20%. Apple's SG&A was $74.57M, missing the average forecast of $87.51M by -14.78%. Lastly, the company's EPS was $-0.002, missing the average prediction of $-1.996 by -99.90%. In terms of the last quarterly report (Dec 2023), TELA Bio's revenue was $17M, beating the average analysts' forecast of $16.46M by 3.27%. The company's EBITDA was $-12.117M, missing the average prediction of $-15.414M by -21.39%. TELA Bio's net income was $-12.89M, beating the average estimation of $-10.991M by 17.27%. The company's SG&A was $21.22M, missing the average forecast of $24.38M by -12.99%. Lastly, the company's EPS was $-0.53, beating the average prediction of $-0.446 by 18.92%